News | Heart Valve Technology | November 10, 2016

First Patient Treated in U.S. Trial of NeoChord DS1000 System

RECHORD Trial will assess safety and effectiveness of off-pump, minimally invasive repair device for degenerative mitral regurgitation

NeoChord, RECHORD Trial, first patient, DS1000 System, degenerative mitral regurgitation, DMR

November 10, 2016 — NeoChord Inc. announced the first use of its DS1000 System in the United States as it enrolled the first patient in the RECHORD Trial.

The RECHORD Trial is a prospective, multicenter, randomized U.S. Food and Drug Administration (FDA) pivotal study intended to establish the safety and effectiveness of the DS1000 System as an alternative to standard surgical mitral valve repair. The study was approved to enroll up to 585 subjects at up to 20 U.S. centers. This study is the first trial of its kind to treat degenerative mitral regurgitation (DMR) patients that have ruptured or elongated chordae tendinae in a trans-apical, beating heart procedure.

David H. Adams, M.D., cardiac surgeon-in-chief, Mount Sinai Health System, and his team successfully treated the first patient in the RECHORD Trial at The Mount Sinai Hospital in New York, N.Y. Adams, national co-principal investigator of the trial, noted, “The success that we observed with our first patient in the trial is very promising and is indicative of the strong clinical results observed in Europe in appropriately selected patients with degenerative mitral valve regurgitation.”

“NeoChord’s technology has the potential to empower surgeons to intervene earlier in the disease process than previously possible and before significant ventricular changes occur,” said Co-Principal Investigator Michael A. Borger, M.D., Ph.D., professor and director, Cardiovascular Institute, New York Presbyterian Hospital/Columbia University Medical Center in New York, NY. “Clinical evidence that demonstrates the benefit of earlier intervention would truly transform the surgical treatment paradigm for patients suffering from DMR.”

In standard mitral valve repair procedures, patients are placed on cardiopulmonary bypass — the heart is arrested while the mitral valve is exposed and repaired. NeoChord’s DS 1000 System technology allows for a truly minimally invasive procedure via a transapical puncture on a beating heart without the need for cardio-pulmonary bypass or aortic cross-clamping. As a result, the invasiveness of the repair procedure is significantly reduced. With the NeoChord procedure, the surgeon uses real-time echocardiographic feedback in the operating room (OR) to precisely adjust the length of the newly placed chords and to reduce and/or eliminate mitral valve regurgitation, while the heart is beating and functioning.

The NeoChord DS1000 System is CE marked and approved for sale in Europe. It is an investigational device in the United States, limited by federal law to investigational use.

For more information: www.neochord.com

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Overlay Init